A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures

BACKGROUND: Biliary tract cancer (BTC) and benign biliary strictures can be difficult to differentiate using standard tumour markers such as serum carbohydrate antigen 19-9 (CA19-9) as they lack diagnostic accuracy. METHODS: Two-dimensional difference gel electrophoresis and tandem mass spectrometry...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandanayake, N S, Sinclair, J, Andreola, F, Chapman, M H, Xue, A, Webster, G J, Clarkson, A, Gill, A, Norton, I D, Smith, R C, Timms, J F, Pereira, S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241550/
https://www.ncbi.nlm.nih.gov/pubmed/21970875
http://dx.doi.org/10.1038/bjc.2011.376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241550/
https://www.ncbi.nlm.nih.gov/pubmed/21970875
http://dx.doi.org/10.1038/bjc.2011.376

Ejemplares similares